Current therapy of vulvovaginitis.
Trichomoniasis is reliably treated with a single 2-g dose of metronidazole; however, with this regimen simultaneous treatment of sexual partners is particularly important. Trichomoniasis in pregnant women, who should not receive metronidazole, might be treated initially with clotrimazole vaginal suppositories, which appear to cure about 50% of cases. Topical antifungal agents of the imidazole class are superior to polyenes in treating vulvovaginal candidiasis. Boric acid powder applied intravaginally in gelatin capsules for 14 days appears as effective as imidazoles. Nonspecific vaginitis is now recognized as involving infection with anaerobic bacteria of the vaginal flora as well as Gardnerella vaginalis. The condition is most successfully treated with a seven-day course of metronidazole, which probably acts by eradicating the anaerobes. In addition, metabolites of metronidazole may act directly on G. vaginalis. Sulfanilamide-aminacrine-allantoin preparations are much less effective than specific therapies and have no role in the treatment of vulvovaginitis.
D000935:Antifungal Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D001888:Boric Acids / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy*; D003022:Clotrimazole / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use*; D011247:Pregnancy; D014247:Trichomonas Vaginitis / Q000188:drug therapy*; D014627:Vaginitis / Q000188:drug therapy; D014848:Vulvovaginitis / Q000188:drug therapy*
D000935:Antifungal Agents; D001888:Boric Acids; D007093:Imidazoles; D008795:Metronidazole; D003022:Clotrimazole